## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.7% in mid entry zone (4.0-10.0%), top 1% cross-sectional ranking. Short-term MRS_5 (2.5%) confirms momentum alignment. Strong momentum (+2.2% 5-day acceleration). Outperforming sector by 6.6%. Caution: overbought RSI (81).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.98)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders**
- Source: FOX40 News | 20251229T080834 | Bearish | Relevance: 100%
- A class action securities lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) by Levi & Korsinsky, LLP, on behalf of shareholders who suffered losses due to alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims that Viatris misrepresented the impact of a warning letter from the FDA regarding its Indore, India facility, leading to a significant stock price decline after the company released disappointing financial results and guidance for 2025. Shareholders are encouraged to learn about their rights to seek recovery.

**2. Investor Alert: Deadline Approaching to Join Viatris Inc. (VTRS) Class Action - Contact Levi & Korsinsky**
- Source: WJHL | 20251228T100845 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has announced a class action securities lawsuit against Viatris Inc. (NASDAQ:VTRS) for shareholders who suffered losses due to alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter on its Indore, India facility, leading to a significant stock price drop following disappointing 2025 financial guidance. Investors are encouraged to contact the firm to learn about their rights to recovery without cost or obligation.

**3. Dementia Drugs Market 2025 Outlook: In-Depth Insights,**
- Source: openPR.com | 20251230T110802 | Somewhat-Bullish | Relevance: 70%
- The global Dementia Drugs Market is projected to grow from US$26.14 Billion in 2025 to US$41.45 Billion by 2032, exhibiting a CAGR of 6.8%. This growth is driven by increasing industry demand and technological advancements, as highlighted in a new report by Coherent Market Insights. The report provides detailed insights into market dynamics, competitive landscapes, regional analysis, and identifies key companies and growth opportunities within the sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Volume divergence: price rising (+2.2% MRS) on declining volume (65% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.07 indicates undervaluation relative to growth. Forward P/E 5.1x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.60 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.07 |
| Forward P/E | 5.1 |
| Current P/E | 5.4 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 5.5% to 7.7% (+2.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 98th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 7.8% shows strong absolute momentum above own 20MA. Outperforming sector by 6.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 81, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.69% (CS: 99) | Strong |
| RSI_14 | 80.7 | Overbought |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.078x | Above |
| vs SMA50 | 1.145x | Above |
| vs SMA200 | 1.303x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $12.54
- **Stop Loss:** $11.98 (4.5% risk)
- **Target:** $13.38 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2357
- **Position Value:** $29,556.78
- **Portfolio %:** 29.56%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*